Halozyme Therapeutics (HALO) Tops Q1 EPS by 13c, provides guidance
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $103.00 +4.40%
Financial Fact:
Revenues under collaborative agreements: 5.49M
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Revenues under collaborative agreements: 5.49M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q1 EPS of $1.11, $0.13 better than the analyst estimate of $0.98. Revenue for the quarter came in at $265 million versus the consensus estimate of $229.29 million.
GUIDANCE:
Halozyme Therapeutics sees FY2025 EPS of $5.30-$5.70, versus the consensus of $5.00. Halozyme Therapeutics sees FY2025 revenue of $1.2-1.28 billion, versus the consensus of $1.191 billion.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
- CalPrivate Bank names Andra Frazier as chief credit officer
- Yalla Group Limited (YALA) Reports Q2 EPS of $0.24
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
